Research & Regulatory News

TRIUMPH-5: The Retatrutide vs Tirzepatide Head-to-Head

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

TRIUMPH-5 (NCT06662383) is a Phase 3 trial comparing retatrutide directly against tirzepatide in 800 adults with obesity. It began in November 2024, and its primary completion was scheduled for November 2026. It will be the first head-to-head test of a triple agonist against a dual agonist.

Key facts

Registration
NCT06662383
Acronym
TRIUMPH-5
Comparison
Retatrutide vs tirzepatide (LY3298176)
Phase
3
Enrolment
800 participants
Started
1 November 2024
Primary completion
Scheduled for November 2026
Status
Active, not recruiting

Why a head-to-head matters more than another placebo trial

Every comparison currently made between retatrutide and tirzepatide is indirect: TRIUMPH-1's 28.3% against SURMOUNT-1's 20.9%, from separate trials with different populations, durations and estimands. Indirect comparison is the weakest form of evidence for this question. TRIUMPH-5 randomises the same population to both drugs at the same time for the same duration, which removes nearly every confound at once.

What is being tested

Retatrutide is a triple agonist engaging GIP, GLP-1 and glucagon receptors. Tirzepatide is a dual agonist engaging GIP and GLP-1. Both are Eli Lilly compounds built on modified GIP scaffolds, so the trial isolates one variable fairly cleanly: what the glucagon-receptor arm adds. That is an interesting scientific question as well as a commercial one.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Scale and timing

The trial enrolled 800 participants, began on 1 November 2024, and its primary completion was scheduled for November 2026. It is listed as active but no longer recruiting. Primary completion is when the last participant completes the primary outcome measurement. It is not the date results are published, and topline release typically follows some months later.

What it will and will not settle

It should settle whether a triple agonist outperforms the best available dual agonist on weight reduction, and how the two compare on tolerability at maximum tolerated doses. It will not address durability after cessation, which is a separate question handled by TRIUMPH-6, and it will not produce cardiovascular outcome data, which requires a different trial design entirely.

The regulatory position is unchanged

Tirzepatide holds marketing authorisations. Retatrutide holds none anywhere, and a head-to-head trial does not alter that. Lilly has signalled an FDA filing in the first quarter of 2027. Nothing in this trial makes retatrutide available outside a registered study, and material supplied for laboratory research is not related to either product.

Frequently asked questions

When will TRIUMPH-5 results be available?

Primary completion was scheduled for November 2026. That is when the last participant completes the primary measurement; topline results typically follow some months later.

Why compare two drugs from the same company?

Because it isolates the scientific question. Both are built on modified GIP scaffolds, so the main difference is retatrutide's glucagon-receptor activity.

Does this mean retatrutide is close to approval?

No. It remains investigational everywhere. Lilly has signalled an FDA filing in Q1 2027, and filing begins a review rather than ending one.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.